[Form 4] Vaxcyte, Inc. Insider Trading Activity
Andrew Guggenhime, listed as President and CFO of Vaxcyte, Inc. (PCVX) and a director, reported multiple dispositions of common stock tied to the vesting of restricted stock units (RSUs). On 09/02/2025 he surrendered 1,270, 2,381, and 1,429 shares to the issuer to cover tax withholding at a price of $31.56 per share. After those transactions his reported beneficial ownership in the class was 131,009, 128,628, and 127,199 shares on the separate reported lines. The filing notes that the total includes 329 shares acquired under the company Employee Stock Purchase Plan on May 16, 2025. The transactions appear to be routine tax-withholding actions related to RSU vesting.
Andrew Guggenhime, indicato come Presidente e CFO di Vaxcyte, Inc. (PCVX) e membro del consiglio, ha dichiarato più cessioni di azioni ordinarie correlate al vesting di restricted stock units (RSU). In data 02/09/2025 ha consegnato all’emittente 1.270, 2.381 e 1.429 azioni per coprire le ritenute fiscali, al prezzo di $31,56 per azione. A seguito di tali operazioni la sua partecipazione beneficiaria riportata nella classe ammontava rispettivamente a 131.009, 128.628 e 127.199 azioni nelle righe distinte del prospetto. Il documento specifica che il totale include 329 azioni acquistate tramite il Piano di Acquisto Azionario dei Dipendenti il 16 maggio 2025. Le operazioni sembrano essere azioni ordinarie di ritenuta fiscale legate al vesting delle RSU.
Andrew Guggenhime, registrado como presidente y director financiero de Vaxcyte, Inc. (PCVX) y miembro del consejo, informó varias enajenaciones de acciones ordinarias vinculadas a la consolidación (vesting) de restricted stock units (RSU). El 02/09/2025 entregó al emisor 1.270, 2.381 y 1.429 acciones para cubrir retenciones fiscales, a un precio de $31,56 por acción. Tras esas operaciones, su propiedad beneficiaria declarada en la clase fue de 131.009, 128.628 y 127.199 acciones en las líneas informadas por separado. El informe indica que el total incluye 329 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados el 16 de mayo de 2025. Las transacciones parecen ser acciones rutinarias de retención fiscal relacionadas con el vesting de las RSU.
Andrew Guggenhime, Vaxcyte, Inc. (PCVX)의 회장이자 최고재무책임자(CFO) 겸 이사로 등재된 인물은 제한주식단위(RSU) 베스팅과 관련한 보통주 다수 처분을 신고했습니다. 2025-09-02에 세금 원천징수용으로 발행사에 1,270, 2,381, 1,429주를 각각 반납했으며 주당 가격은 $31.56였습니다. 해당 거래 후 각 신고 항목에 보고된 그의 실질적 보유 주식 수는 각각 131,009, 128,628, 127,199주였습니다. 신고서에는 총수에 2025년 5월 16일 직원주식 매수계획(ESPP)을 통해 취득한 329주가 포함되어 있다고 명시되어 있습니다. 이 거래들은 RSU 베스팅에 따른 통상적인 세금 원천징수 조치로 보입니다.
Andrew Guggenhime, inscrit en tant que président et directeur financier de Vaxcyte, Inc. (PCVX) et administrateur, a déclaré plusieurs cessions d’actions ordinaires liées au vesting de restricted stock units (RSU). Le 02/09/2025, il a remis à l’émetteur 1 270, 2 381 et 1 429 actions pour couvrir les retenues fiscales, au prix de 31,56 $ par action. Après ces opérations, sa propriété bénéficiaire déclarée pour la catégorie s’élevait respectivement à 131 009, 128 628 et 127 199 actions sur les lignes signalées séparément. le dossier précise que le total inclut 329 actions acquises via le Plan d’Achat d’Actions des Employés le 16 mai 2025. Ces opérations semblent être des actions routinières de retenue fiscale liées au vesting des RSU.
Andrew Guggenhime, als Präsident und CFO von Vaxcyte, Inc. (PCVX) sowie als Direktor gelistet, meldete mehrere Veräußerungen von Stammaktien im Zusammenhang mit dem Vesting von Restricted Stock Units (RSUs). Am 02.09.2025 übergab er dem Emittenten 1.270, 2.381 und 1.429 Aktien zur Deckung von Steuerabzügen zum Preis von $31,56 pro Aktie. Nach diesen Transaktionen betrug sein gemeldetes wirtschaftliches Eigentum an der Aktienklasse in den separaten Meldezeilen jeweils 131.009, 128.628 und 127.199 Aktien. Die Einreichung weist darauf hin, dass die Gesamtsumme 329 Aktien umfasst, die am 16. Mai 2025 über den Employee Stock Purchase Plan des Unternehmens erworben wurden. Die Transaktionen erscheinen als routinemäßige steuerliche Einbehaltshandlungen im Zusammenhang mit dem Vesting der RSUs.
- Continued significant ownership: Reported beneficial holdings remain in the low hundreds of thousands of shares, indicating continued executive alignment with shareholder interests
- Clear disclosure: Form 4 specifies that surrendered shares were for tax withholding and discloses ESPP shares, supporting transparency
- Reduction in beneficial shares: Surrenders totaling 5,080 shares reduced reported holdings, though they were for tax withholding rather than open-market sales
Insights
TL;DR: Routine RSU tax-withholding sales by a senior executive; not a directional trading signal.
The reporting shows three separate share surrenders tied to RSU vesting executed at $31.56 per share to satisfy tax withholding obligations. Such transactions reduce outstanding beneficial ownership but are common when executives receive equity compensation. The remaining reported holdings (in the hundreds of thousands of shares) indicate continued equity exposure to the company. There is no indication in the Form 4 of open-market sales or other cash-disposition motives beyond withholding.
TL;DR: Standard compliance disclosure for RSU vesting and tax withholding; governance processes appear followed.
The Form 4 identifies the reporting person as an officer and director and documents share withholding to cover tax obligations from vested RSUs, a routine corporate practice. The inclusion of ESPP-acquired shares in the aggregate beneficial ownership is clearly disclosed. No departures from typical Section 16 reporting practices are evident based on the disclosed entries.
Andrew Guggenhime, indicato come Presidente e CFO di Vaxcyte, Inc. (PCVX) e membro del consiglio, ha dichiarato più cessioni di azioni ordinarie correlate al vesting di restricted stock units (RSU). In data 02/09/2025 ha consegnato all’emittente 1.270, 2.381 e 1.429 azioni per coprire le ritenute fiscali, al prezzo di $31,56 per azione. A seguito di tali operazioni la sua partecipazione beneficiaria riportata nella classe ammontava rispettivamente a 131.009, 128.628 e 127.199 azioni nelle righe distinte del prospetto. Il documento specifica che il totale include 329 azioni acquistate tramite il Piano di Acquisto Azionario dei Dipendenti il 16 maggio 2025. Le operazioni sembrano essere azioni ordinarie di ritenuta fiscale legate al vesting delle RSU.
Andrew Guggenhime, registrado como presidente y director financiero de Vaxcyte, Inc. (PCVX) y miembro del consejo, informó varias enajenaciones de acciones ordinarias vinculadas a la consolidación (vesting) de restricted stock units (RSU). El 02/09/2025 entregó al emisor 1.270, 2.381 y 1.429 acciones para cubrir retenciones fiscales, a un precio de $31,56 por acción. Tras esas operaciones, su propiedad beneficiaria declarada en la clase fue de 131.009, 128.628 y 127.199 acciones en las líneas informadas por separado. El informe indica que el total incluye 329 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados el 16 de mayo de 2025. Las transacciones parecen ser acciones rutinarias de retención fiscal relacionadas con el vesting de las RSU.
Andrew Guggenhime, Vaxcyte, Inc. (PCVX)의 회장이자 최고재무책임자(CFO) 겸 이사로 등재된 인물은 제한주식단위(RSU) 베스팅과 관련한 보통주 다수 처분을 신고했습니다. 2025-09-02에 세금 원천징수용으로 발행사에 1,270, 2,381, 1,429주를 각각 반납했으며 주당 가격은 $31.56였습니다. 해당 거래 후 각 신고 항목에 보고된 그의 실질적 보유 주식 수는 각각 131,009, 128,628, 127,199주였습니다. 신고서에는 총수에 2025년 5월 16일 직원주식 매수계획(ESPP)을 통해 취득한 329주가 포함되어 있다고 명시되어 있습니다. 이 거래들은 RSU 베스팅에 따른 통상적인 세금 원천징수 조치로 보입니다.
Andrew Guggenhime, inscrit en tant que président et directeur financier de Vaxcyte, Inc. (PCVX) et administrateur, a déclaré plusieurs cessions d’actions ordinaires liées au vesting de restricted stock units (RSU). Le 02/09/2025, il a remis à l’émetteur 1 270, 2 381 et 1 429 actions pour couvrir les retenues fiscales, au prix de 31,56 $ par action. Après ces opérations, sa propriété bénéficiaire déclarée pour la catégorie s’élevait respectivement à 131 009, 128 628 et 127 199 actions sur les lignes signalées séparément. le dossier précise que le total inclut 329 actions acquises via le Plan d’Achat d’Actions des Employés le 16 mai 2025. Ces opérations semblent être des actions routinières de retenue fiscale liées au vesting des RSU.
Andrew Guggenhime, als Präsident und CFO von Vaxcyte, Inc. (PCVX) sowie als Direktor gelistet, meldete mehrere Veräußerungen von Stammaktien im Zusammenhang mit dem Vesting von Restricted Stock Units (RSUs). Am 02.09.2025 übergab er dem Emittenten 1.270, 2.381 und 1.429 Aktien zur Deckung von Steuerabzügen zum Preis von $31,56 pro Aktie. Nach diesen Transaktionen betrug sein gemeldetes wirtschaftliches Eigentum an der Aktienklasse in den separaten Meldezeilen jeweils 131.009, 128.628 und 127.199 Aktien. Die Einreichung weist darauf hin, dass die Gesamtsumme 329 Aktien umfasst, die am 16. Mai 2025 über den Employee Stock Purchase Plan des Unternehmens erworben wurden. Die Transaktionen erscheinen als routinemäßige steuerliche Einbehaltshandlungen im Zusammenhang mit dem Vesting der RSUs.
FAQ
What transactions did Andrew Guggenhime report for PCVX?
How many shares does Guggenhime beneficially own after the reported transactions?
Do the transactions indicate open-market sales?
Are any Employee Stock Purchase Plan (ESPP) shares included in the ownership total?
What is the reported price per share for the withholding transactions?
